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a  b  s  t  r  a  c  t
Aim:  To  further  explore  the impact  of concomitant  antiepileptic  drugs  (AEDs)  on  the  efﬁcacy  and  tolera-
bility  of  adjunctive  perampanel  for focal  epilepsy.
Methods: Data  were  pooled  from  three  phase  III trials  of adjunctive  perampanel  in patients  (≥12  years
of age)  with  refractory  partial-onset  seizures.  Concomitant  AEDs  were  categorized  according  to  whether
or not  they  were  enzyme-inducing  AEDs  (EIAEDs;  known  to reduce  perampanel  plasma  concentrations)
or  sodium  channel  blockers  (SCBs).  Post  hoc  analyses  assessed  the  impact  of co-administration  of  non-
EIAED  SCBs  and  the  overall  number  of  concomitant  AEDs  on changes  in seizure  frequency,  50% responder
rates,  rates  of treatment-emergent  adverse  events  (TEAEs),  and  rates  of  discontinuation  due  to  TEAEs,  in
patients  randomized  to  receive  daily  placebo  or  perampanel  2, 4, 8, or 12  mg.
Results:  Amongst  1480  randomized  and  treated  patients,  most  were  receiving  two  or more  concomitant
AEDs  (n =  1273,  86.0%),  one  or  more  EIAEDs  (n  =  1083,  73.2%),  and/or  one  or more  SCBs  (n = 1203,  81.3%)
at  Baseline.  The  magnitude  of  seizure  reduction  appeared  unaffected  by  the  presence  of non-EIAED  SCBs,
but lower  in the  presence  of  multiple  AEDs.  Frequency  of  TEAEs  did not  appear  to  be  affected  by  the
presence  of non-EIAED  SCBs  or multiple  AEDs.
Conclusion:  Beyond  the known  interactions  between  perampanel  and  EIAEDs,  perampanel  efﬁcacy
appears  to be  unaffected  by  the  use  of  concomitant  non-EIAED  SCBs,  but may  be  reduced  in  the  presence
of  multiple  concomitant  AEDs  (possibly  indicative  of  the  presence  of  more  refractory  epilepsy).  Nonethe-
less,  with  careful  titration  to  balance  efﬁcacy  and  tolerability,  perampanel  may  be  combined  with  a range
of  AEDs,  facilitating  integration  into  treatment  plans.
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reatment-emergent adverse event.
∗ Corresponding author at: Department of Neurology, Royal Melbourne Hospital,
arkville, VIC 3050, Australia.
E-mail addresses: kwanp@unimelb.edu.au (P. Kwan),
artin.Brodie@glasgow.ac.uk (M.J. Brodie), Antonio Laurenza@eisai.com
A. Laurenza), hannah.ﬁtzgibbon@complete-mc.com (H. FitzGibbon),
arry.gidal@wisc.edu (B.E. Gidal).
ttp://dx.doi.org/10.1016/j.eplepsyres.2015.09.002
920-1211/© 2015 The Authors. Published by Elsevier B.V. This is an open access article
.0/).hed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Current antiepileptic drugs (AEDs) fail to confer seizure freedom
in up to one-third of patients with epilepsy (Brodie et al., 2012),
warranting the development of new agents. New AEDs are ini-
tially evaluated as adjunctive treatments that are added to existing
regimens of AEDs, which may  vary in number and pharmacologic
characteristics. When introducing a new AED, it is important to
consider the potential for interactions with the AEDs that a patient
is already taking, as they may  affect treatment response.
In particular, pharmacokinetic interactions between AEDs often
result from inducing or inhibitory effects on hepatic cytochrome
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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450 (CYP) enzymes, which are responsible for the metabolism of
everal, particularly older-generation, AEDs (Patsalos and Perucca,
003). The evidence for pharmacodynamic interactions between
EDs, as a result of their different mechanisms of action, is more
imited, but of no less importance. Animal studies have indicated
hat combining AEDs with different mechanisms of action may
onfer synergistic effects, particularly for combinations including
-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)
eceptor antagonists (Jonker et al., 2007). In humans, evidence
rom observational studies has suggested synergistic efﬁcacy when
he sodium channel blocker (SCB) lamotrigine is combined with
alproic acid (Brodie and Yuen, 1997; Pisani et al., 1999), and a
etrospective review of a US healthcare claims database has sug-
ested that combining AEDs with different mechanisms of action
ay  offer improved effectiveness compared with combinations
ith the same mechanisms, as measured by prolonged treatment
ontinuation and reduced risks for hospitalization and emergency
epartment visits (Margolis et al., 2014). Other recent efforts to
dentify potentially beneﬁcial AED combinations have utilized post
oc analyses of data from pivotal trials (Sake et al., 2010).
Perampanel is a noncompetitive AMPA receptor antagonist,
pproved globally as an adjunctive treatment for partial-onset
eizures, with or without secondary generalization, in patients
ged 12 years and older (European Medicines Agency, 2012; Food
nd Drug Administration, 2012). Approval was based on three
lacebo-controlled phase III pivotal studies in a total of 1480
atients with refractory partial-onset seizures who  were receiv-
ng 1–3 concomitant AEDs (French et al., 2012, 2013; Krauss et al.,
012). As expected from the metabolism of perampanel by CYP3A4
European Medicines Agency, 2012), pooled data from these studies
ndicated that enzyme-inducing AEDs (EIAEDs) reduced peram-
anel plasma concentrations without affecting the relationship
etween plasma concentration and reduction in seizure frequency
Gidal et al., 2013). This was consistent with the pharmacokinetic
ffects of hepatic enzyme induction/inhibition previously reported
n the literature (Johannessen Landmark et al., 2012; Patsalos,
013).
Subsequently, separate pooled analyses explored efﬁcacy and
afety outcomes when perampanel was co-administered with
IAEDs, conﬁned to those demonstrated to confer clinically
mportant induction of perampanel metabolism: carbamazepine,
xcarbazepine, and phenytoin (Gidal et al., 2015). These analyses,
ased on actual (last) dose of perampanel, indicated that the efﬁ-
acy of perampanel was reduced in the presence of these EIAEDs.
onsistent with this, other pooled analyses, based on randomized
erampanel dose, also showed a reduction of perampanel efﬁ-
acy in the presence of carbamazepine, although the non-EIAEDs
amotrigine, levetiracetam, and valproic acid had no clear impact
Steinhoff et al., 2013).
Overall, some clinically important inducers of perampanel
etabolism (carbamazepine, oxcarbazepine, and phenytoin) have
een characterized in terms of their impact on perampanel efﬁ-
acy. However, beyond this, data appear lacking on the impact
f other aspects of concomitant AED use, including other mech-
nisms of action. To help physicians integrate perampanel into
reatment plans, we report post hoc analyses of the pooled phase III
ata by randomized dose, to further evaluate potential interactions
etween perampanel and concomitant AEDs. For the ﬁrst time, the
mpact of concomitant administration of SCBs, and the impact of the
umber of concomitant AEDs is evaluated, with consideration of
ny potentially confounding effects of EIAEDs, including those not
reviously demonstrated to confer clinically important induction
f perampanel metabolism. These analyses are intended to provide
ew insight into the importance of considering the different mech-
nisms of action and number of concomitant AEDs when initiating
reatment with perampanel.ch 117 (2015) 117–124
2. Methods
2.1. Overall phase III program
The double-blind, randomized, parallel-group studies 304 (Clin-
icalTrials.gov identiﬁer: NCT00699972), 305 (NCT00699582), and
306 (NCT00700310) were conducted between April 2008 and
January 2011, with patients enrolled from >40 countries across
ﬁve continents. The designs and outcomes of these studies have
been previously reported in full (French et al., 2012, 2013; Krauss
et al., 2012). In brief, eligible patients were aged ≥12 years and
were experiencing partial-onset seizures despite treatment with
1–3 AEDs. Patients could only be receiving one of the following
AEDs: carbamazepine, phenytoin, phenobarbital, or primidone –
these AEDs were considered EIAEDs at the outset of the studies,
although, in subsequent analysis of perampanel plasma concentra-
tions and pharmacokinetic modeling of the pooled phase III data,
clinically important induction of perampanel metabolism was only
demonstrable for carbamazepine, oxcarbazepine, and phenytoin
(based on presence vs absence of each concomitant treatment)
(Gidal et al., 2015).
Following a 6-week Baseline Period, patients were randomized
to once-daily double-blind treatment with placebo or perampanel
(8 mg  or 12 mg  in studies 304 and 305; 2 mg,  4 mg,  or 8 mg  in study
306). In each Double-Blind Phase, perampanel was uptitrated to
the randomized dose in weekly increments of 2 mg  over a 6-week
Titration Period. Patients then continued to receive the random-
ized dose for a 13-week Maintenance Period. Dose reduction due
to intolerability was permitted.
The number of seizures per day was recorded in a daily patient
diary. Any adverse events (AEs) that were new or worsened during
the Double-Blind Phase were recorded as treatment-emergent AEs
(TEAEs), and were classiﬁed according to the Medical Dictionary
for Regulatory Activities (version 13.0 for studies 304 and 306, and
version 13.5 for study 305).
2.2. Post hoc analyses of the impact of concomitant AEDs
The objective of the present analyses was to further evaluate
potential interactions between perampanel and other AEDs based
on mechanism of action and number of concomitant AEDs.
Since the efﬁcacy of perampanel is already known to be reduced
in the presence of EIAEDs that induce perampanel metabolism,
these analyses explored effects both in the presence and absence
of EIAEDs. EIAEDs were deﬁned here as carbamazepine, oxcar-
bazepine, phenytoin, eslicarbazepine, phenobarbital, primidone,
or topiramate. This deﬁnition encompassed the AEDs previously
demonstrated to cause clinically important induction of peram-
panel metabolism (group 1 EIAEDs: carbamazepine, oxcarbazepine,
and phenytoin), but also other AEDs typically recognized as EIAEDs
that had not demonstrated such a clear inducing effect in previous
analyses of perampanel data, possibly due to small patient num-
bers in some cases (group 2 EIAEDs: eslicarbazepine, phenobarbital,
primidone, and topiramate).
As sodium channel blockade is one of the most common mech-
anisms of action of AEDs, the impact of the co-administration of
SCBs on perampanel efﬁcacy and safety was evaluated. SCBs were
deﬁned here as carbamazepine, eslicarbazepine, oxcarbazepine,
phenytoin, lacosamide, lamotrigine, or ruﬁnamide. To help delin-
eate the effects of EIAEDs and SCBs, these analyses focused on the
three SCBs that were not also EIAEDs (lacosamide, lamotrigine,
and ruﬁnamide). Patients were therefore categorized according to
whether or not they had received any EIAEDs, and whether or not
they had received any non-EIAED SCBs.
To evaluate the impact of the number of concomitant AEDs
on perampanel efﬁcacy and safety, patients were categorized
Resear
a
c
E
e
o
a
D
r
M
p
t
w
f
p
p
o
i
w
c
r
d
r
b
2
c
l
C
a
a
r
m
w
3
3
t
a
T
p
l
d
o
(
r
8
t
o
a
(
c
l
3
i
3
tP. Kwan et al. / Epilepsy 
ccording to whether they had received one, two, or three con-
omitant AEDs, and whether those concomitant AEDs included no
IAEDs or one EIAED (patients receiving more than one EIAED were
xcluded from this analysis to avoid confounding effects).
Analyses were performed to assess the impact of mechanism
f action and number of concomitant AEDs on median percent-
ge change in overall seizure frequency per 28 days (Baseline vs
ouble-Blind Phase) and 50% responder rate (patients with >50%
eduction from Baseline in seizure frequency per 28 days in the
aintenance Period) in patients randomized to receive placebo or
erampanel. Efﬁcacy analyses were based on the pooled intent-to-
reat analysis set, consisting of all randomized and treated patients
ith any post-Baseline seizure data, with last observation carried
orward. All efﬁcacy analyses were based on randomized peram-
anel dose. Median percentage change in overall seizure frequency
er 28 days was compared between groups, based on a rank analysis
f covariance with Baseline AED category as a factor, prerandom-
zation seizure frequency as a covariate, and 50% responder rate
as compared between groups using Fisher’s exact test.
Analyses were also performed to assess the impact of these con-
omitant AEDs on the frequencies of the 10 most common TEAEs
eported across the phase III studies (Steinhoff et al., 2013), and
iscontinuations due to TEAEs, based on the safety analysis set (all
andomized and treated patients). TEAE incidence was compared
etween groups using Fisher’s exact test.
.3. Standard protocol approvals, registrations, and patient
onsents
All studies were performed in accordance with the Dec-
aration of Helsinki, Good Clinical Practice ICH-E6 Guideline
PMP/ICH/135/95, European Clinical Trial Directive 2001/20/EC,
nd the US Code of Federal Regulations Part 21. Trial protocols,
mendments, and informed consent were reviewed by national
egulatory authorities in each country and independent ethics com-
ittees or institutional review boards for each site. All patients gave
ritten, informed consent before participation.
. Results
.1. Patients
A total of 1480 patients were randomized and treated in the
hree phase III pivotal studies. Demographics for this pooled safety
nalysis set have been reported previously (Steinhoff et al., 2013).
he use of concomitant AEDs at Baseline is shown in Table 1. Most
atients were receiving two or more concomitant AEDs at Base-
ine (one, n = 206, 13.9%; two, n = 751, 50.7%; three, n = 522, 35.3%;
ata missing for one patient), and the majority were receiving
ne or more EIAEDs (n = 1083, 73.2%) and/or one or more SCBs
n = 1203, 81.3%). Of the patients receiving EIAEDs (n = 1083), most
eceived carbamazepine, oxcarbazepine and/or phenytoin (n = 866,
0.0%), which are known to be associated with clinically impor-
ant induction of perampanel metabolism, but few received two
r more of these three agents (n = 16, 1.5%). The most commonly
dministered concomitant EIAEDs were the SCBs carbamazepine
n = 491, 33.2%) and oxcarbazepine (n = 270, 18.2%), while the most
ommonly administered concomitant non-EIAEDs were the SCB
amotrigine (n = 458, 30.9%) and the non-SCBs valproic acid (n = 478,
2.3%) and levetiracetam (n = 435, 29.4%). There were 1478 patients
ncluded in the pooled intent-to-treat analysis set..2. Impact of concomitant AEDs on perampanel efﬁcacy
When patients were categorized according to whether or not
hey had received any EIAEDs, and whether or not they had receivedch 117 (2015) 117–124 119
any non-EIAED SCBs, Baseline patient demographics (gender, age,
BMI) remained largely balanced between groups (Table 2) How-
ever, there was some variation in terms of epilepsy characteristics.
Most notably, there was broad inter-patient variation in Base-
line seizure frequency: while median values appeared balanced
between groups (10.9–13.1), individual values ranged from 1.4 to
4504 seizures per 28 days. Similarly, mean time since epilepsy diag-
nosis was largely balanced between groups (217.0–258.8 months),
but large standard deviations indicated broad inter-patient vari-
ability (range was  6.0–819.0 months). In addition, the number of
concomitant AEDs at Baseline varied between groups; for example,
the use of just one concomitant AED at Baseline was most frequent
in patients who  were not receiving any EIAEDs, while the use of
three concomitant AEDs at Baseline was most frequent in patients
who were receiving one or more EIAEDs.
In accordance with previously reported analyses, median reduc-
tions in seizure frequency and 50% responder rates were generally
greater in patients randomized to receive perampanel 4–12 mg
than in those randomized to placebo (Fig. 1). Perampanel exposure
was reduced in the presence of EIAEDs (Table 3) and there were
corresponding reductions in efﬁcacy in this setting (Fig. 1).
Efﬁcacy outcomes with perampanel 12 mg appeared to be
reduced to a similar extent in patients receiving group 1 EIAEDs
(those previously demonstrated to cause clinically important
induction of perampanel metabolism: carbamazepine, oxcar-
bazepine, and phenytoin) as in those receiving group 2 EIAEDs
(those that had not previously demonstrated such clear induction
of perampanel metabolism: eslicarbazepine, phenobarbital, prim-
idone, and topiramate; Table 4). However, in patients treated with
perampanel 8 mg,  the impact of group 2 EIAEDs was weaker than
that of the group 1 EIAEDs, while in patients treated with per-
ampanel 4 mg,  the group 2 EIAEDs were not associated with any
reductions in efﬁcacy. Alongside these observations, it should be
noted that perampanel exposure was shown to be reduced in the
presence of group 2 EIAEDs, but the effect was weaker than that of
the group 1 EIAEDs (Table 3).
The presence or absence of non-EIAED SCBs had no clear, con-
sistent impact on efﬁcacy outcomes with perampanel, regardless of
whether patients were also receiving concomitant EIAEDs (Fig. 1).
3.3. Impact of the number of concomitant AEDs on perampanel
efﬁcacy
In patients who  were not receiving any concomitant EIAEDs, the
efﬁcacy of pooled doses of perampanel 2–12 mg  declined as the
number of concomitant AEDs increased from one to three (Fig. 2).
In patients who  were receiving one concomitant EIAED, there was
a similar but less marked trend.
3.4. Impact of concomitant AEDs on perampanel tolerability
Overall, in patients randomized to receive perampanel 2–12 mg,
there were signiﬁcantly lower rates of TEAEs leading to discontin-
uation in patients who were receiving concomitant EIAEDs than in
those who  were not (7.1% vs 16.1%, respectively, p < 0.001; Table 5).
However, the frequencies of individual TEAEs appeared largely
similar regardless of whether EIAEDs or non-EIAED SCBs were co-
administered (Table 5). The exceptions were the following three
TEAEs, which were signiﬁcantly less common in patients receiv-
ing one or more EIAEDs compared with those receiving no EIAEDs:
fatigue (7.3% vs 11.8%, respectively, p < 0.05), nausea (4.0% vs 8.6%,
p < 0.01), and ataxia (2.5% vs 6.1%, p < 0.05).
There were no clear trends in the frequencies of TEAEs with
regard to the number of concomitant AEDs received, either in the
presence or absence of one EIAED (Table 6).
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Table 1
Concomitant AEDs at Baseline (pooled safety analysis set).
Placebo (n = 442) Perampanel
2 mg  (n = 180) 4 mg (n = 172) 8 mg  (n = 431) 12 mg (n = 255)
Non-EIAED, non-SCB, n (%)
Valproic acid 140 (31.7) 80 (44.4) 75 (43.6) 120 (27.8) 63 (24.7)
Levetiracetam 125 (28.3) 48 (26.7) 45 (26.2) 130 (30.2) 87 (34.1)
Clobazam 46 (10.4) 17 (9.4) 20 (11.6) 43 (10.0) 25 (9.8)
Clonazepam 50 (11.3) 12 (6.7) 10 (5.8) 29 (6.7) 20 (7.8)
Zonisamide 39 (8.8) 12 (6.7) 7 (4.1) 36 (8.4) 23 (9.0)
Pregabalin 27 (6.1) 11 (6.1) 7 (4.1) 21 (4.9) 17 (6.7)
Gabapentin 6 (1.4) 4 (2.2) 4 (2.3) 4 (0.9) 7 (2.7)
Felbamate 6 (1.4) 0 (0.0) 0 (0.0) 3 (0.7) 6 (2.4)
Tiagabine 3 (0.7) 1 (0.6) 3 (1.7) 5 (1.2) 0 (0.0)
Lorazepam 4 (0.9) 0 (0.0) 0 (0.0) 1 (0.2) 5 (2.0)
Diazepam 2 (0.5) 2 (1.1) 1 (0.6) 2 (0.5) 2 (0.8)
Clorazepic acid 3 (0.7) 0 (0.0) 1 (0.6) 1 (0.2) 3 (1.2)
Acetazolamide 3 (0.7) 0 (0.0) 1 (0.6) 1 (0.2) 0 (0.0)
Sulthiame 2 (0.5) 0 (0.0) 0 (0.0) 2 (0.5) 1 (0.4)
Ethosuximide 0 (0.0) 1 (0.6) 0 (0.0) 2 (0.5) 1 (0.4)
Bromazepam 1 (0.2) 0 (0.0) 1 (0.6) 1 (0.2) 0 (0.0)
Gidazepam 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nitrazepam 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Phenazepam 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Alprazolam 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0)
Estazolam 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0)
Lormetazepam 0 (0.0) 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0)
Mesuximide 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0)
Oxazepam 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Temazepam 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0)
Non-EIAED, SCB, n (%)
Lamotrigine 125 (28.3) 56 (31.1) 68 (39.5) 146 (33.9) 63 (24.7)
Lacosamide 14 (3.2) 4 (2.2) 2 (1.2) 14 (3.2) 12 (4.7)
Ruﬁnamde 5 (1.1) 0 (0.0) 0 (0.0) 3 (0.7) 3 (1.2)
EIAED, non-SCB, n (%)
Topiramate 90 (20.4) 38 (21.1) 40 (23.3) 81 (18.8) 45 (17.6)
Phenobarbital 24 (5.4) 5 (2.8) 10 (5.8) 23 (5.3) 8 (3.1)
Primidone 10 (2.3) 1 (0.6) 0 (0.0) 5 (1.2) 7 (2.7)
EIAED, SCB, n (%)
Carbamazepine 143 (32.4) 58 (32.2) 56 (32.6) 138 (32.0) 96 (37.6)
Oxcarbazepine 88 (19.9) 35 (19.4) 25 (14.5) 78 (18.1) 44 (17.3)
Phenytoin 28 (6.3) 15 (8.3) 13 (7.6) 39 (9.0) 25 (9.8)
A  chan
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ED (antiepileptic drug), EIAED (enzyme-inducing antiepileptic drug), SCB (sodium
. DiscussionOverall, the present analyses indicate that the efﬁcacy and tol-
rability proﬁles of perampanel remain largely consistent with
he previously reported overall pooled phase III data (Steinhoff
t al., 2013), with therapeutic beneﬁt observed irrespective of the
able 2
atient Baseline characteristics by type of concomitant AEDs.
No EIAEDs/no non-EIAED
SCBs (n = 148)
No EIAE
non-EIA
Female, n (%) 74 (50.0) 139 (56
Mean  age (SD), years 34.6 (14.6) 36.1 (
Mean  body mass index (SD), kg/m2 24.8 (5.6) 25.4 (
Mean  time since epilepsy diagnosis (SD), months 217.0 (143.3) 251.2 (
Seizure  history, n (%)
Simple partial seizures, with/without motor
signs
49 (33.1) 84 (33
CP  seizures 127 (85.8) 221 (89
CP  + SG seizures 98 (66.2) 176 (71
Median Baseline seizure frequency per 28 days
(min, max), n
13.1 (2.4, 1031) 10.9 (
No.  of concomitant AEDs at Baseline, n (%)
1 58 (39.2) 39 (15
2  74 (50.0) 140 (56
3  16 (10.8) 69 (27
ED (antiepileptic drug), CP (complex partial), EIAED (enzyme-inducing antiepileptic dru
lized).0 (0.0) 0 (0.0) 0 (0.0)
nel blocker).
presence or absence of various categories of concomitant AEDs.
Compared with placebo, there were generally improvements in
seizure frequency and responder rates at perampanel doses of
4–12 mg,  and dizziness, somnolence, and headache were amongst
the most frequently reported TEAEs when all perampanel doses
were pooled.
Ds/one or more
ED SCBs (n = 248)
One or more EIAEDs/no
non-EIAED SCBs (n = 830)
One or more EIAEDs/one or
more non-EIAED SCBs (n = 252)
.0) 420 (50.6) 126 (50.0)
13.2) 34.6 (13.9) 34.6 (12.6)
5.1) 24.8 (5.6) 25.4 (5.2)
148.3) 258.8 (159.9) 255.1 (138.8)
.9) 262 (31.6) 90 (35.7)
.1) 695 (83.7) 221 (87.7)
.0) 571 (68.8) 182 (72.2)
3.3, 1065) 10.9 (1.4, 4504) 12.1 (2.9, 1083)
.7) 109 (13.1) 0 (0.0)
.5) 430 (51.8) 105 (41.7)
.8) 291 (35.1) 147 (58.3)
g), SCB (sodium channel blocker), SD (standard deviation), SG (secondarily gener-
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Fig. 1. Median percentage changes in seizure frequency per 28 days (Baseline vs Double-blind Treatment Period) and 50% responder rates (Baseline vs Maintenance Period)
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o ore no
b
p
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p
an  patients receiving placebo or perampanel 2–12 mg  in combination with: (A) no 
r  more EIAEDs and no non-EIAED SCBs, or (D) one or more EIAEDs and one or m
locker).
Also consistent with previously reported analyses, peram-
anel exposure was reduced in the presence of EIAEDs, with
orresponding reductions in efﬁcacy. Group 2 EIAEDs, which
ad not demonstrated clinically important induction of peram-
anel metabolism, were shown to reduce perampanel exposure,
lthough to a lesser extent than the established group 1s and no non-EIAED SCBs, (B) no EIAEDs and one or more non-EIAED SCBs, (C) one
n-EIAED SCBs. EIAED (enzyme-inducing antiepileptic drug), SCB (sodium channel
EIAEDs. Group 1 and group 2 EIAEDs were associated with
similar reductions in efﬁcacy when co-administered with per-
ampanel 12 mg,  but the impact of the group 2 EIAEDs was
less pronounced in patients receiving lower perampanel doses,
perhaps due to the observed weaker effect on perampanel
exposure. Nonetheless, the analyses provide overall evidence
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Table 3
Steady-state perampanel plasma concentrations (CavSS) according to perampanel dose and the presence of concomitant EIAEDs, including group 1 EIAEDs (carbamazepine,
oxcarbazepine, and phenytoin), and group 2 EIAEDs (phenobarbital, primidone, and topiramate; no patients were receiving the group 2 EIAED eslicarbazepine).
Perampanel
2 mg  4 mg 8 mg 12 mg
Patients receiving one or more EIAEDs (group 1 or group 2)
Patient number, n 588 585 1327 666
Mean  CavSS (SD) 69.7 (51.0) 145.2 (118.6) 274.6 (222.0) 356.7 (215.5)
Patients receiving one or more group 1 EIAEDs, and no group 2 EIAEDs
Patient number, n 373 345 910 466
Mean  CavSS (SD) 57.6 (32.3) 116.8 (93.6) 236.2 (173.0) 303.8 (187.4)
Patients receiving one or more group 2 EIAEDs, and no group 1 EIAEDs
Patient number, n 120 158 249 110
Mean  CavSS (SD) 121.8 (73.1) 230.3 (142.5) 484.3 (299.0) 553.9 (233.7)
Patients receiving no EIAEDs
Patient number, n 226 220 428 125
Mean  CavSS (SD) 157.2 (79.9) 389.0 (302.9) 648.1 (387.9) 907.4 (446.8)
EIAED (enzyme-inducing antiepileptic drug), SD (standard deviation).
Table 4
Median percentage changes in seizure frequency per 28 days (Baseline vs Double-blind Treatment Period) and 50% responder rates (Baseline vs Maintenance Period) in
patients receiving placebo or perampanel 2–12 mg  in combination with 1–3 concomitant AEDs, including: one or more group 1 EIAEDs (carbamazepine, oxcarbazepine, and
phenytoin), one or more group 2 EIAEDs (eslicarbazepine, phenobarbital, primidone, and topiramate), or no EIAEDs.
Placebo (n = 441) Perampanel
2 mg (n = 180) 4 mg (n = 172) 8 mg  (n = 431) 12 mg (n = 254)
Patient numbers, n
One or more group 1 EIAEDs 254 105 93 251 162
One  or more group 2 EIAEDs 122 42 49 102 57
No  EIAEDs 117 51 47 119 62
Median change in seizure frequency, %
One or more group 1 EIAEDs −11.7 −7.7 −24.7 −22.8 −18.3
One  or more group 2 EIAEDs −5.4 −18.5 −29.8 −34.9 −16.2
No EIAEDs −21.0 −15.4 −19.0 −36.3 −48.2
50%  responder rate, %
One or more group 1 EIAEDs 20.5 19.0 23.7 27.5 29.0
One  or more group 2 EIAEDs 19.7 26.2 34.7 37.3 28.1
A
o
s
s
d
c
t
s
T
F
*
T
ENo  EIAEDs 18.8 19.6 
ED (antiepileptic drug), EIAED (enzyme-inducing antiepileptic drug).
f weak enzyme-inducing properties for the group 2 EIAEDs,
upporting the approach to EIAED classiﬁcation in the present
tudy.
Although the frequencies of TEAEs were largely similar, rates of
iscontinuation due to TEAEs were lower in patients who received
oncomitant EIAEDs than in those who did not, implying that
he TEAEs were less severe. Overall, the analyses by EIAED use
uggest that initial titration to a higher dose of perampanel may
able 5
requencies of TEAEs in patients treated with perampanel (pooled doses, 2–12 mg)  with 
TEAE, n (%) No EIAEDs
No EIAEDs
(n = 280)
No EIAEDs/no
non-EIAED SCBs
(n = 96)
No EIAEDs/one
more non-EIA
SCBs (n = 184)
TEAEs leading to discontinuation 45 (16.1) 20 (20.8) 25 (13.6) 
Dizziness 83 (29.6) 32 (33.3) 51 (27.7) 
Somnolence 38 (13.6) 17 (17.7) 21 (11.4) 
Headache 28 (10.0) 10 (10.4) 18 (9.8) 
Fatigue 33 (11.8) 12 (12.5) 21 (11.4) 
Irritability 21 (7.5) 9 (9.4) 12 (6.5) 
Nausea 24 (8.6) 8 (8.3) 16 (8.7) 
Fall  18 (6.4) 9 (9.4) 9 (4.9) 
Nasopharyngitis 17 (6.1) 5 (5.2) 12 (6.5) 
Upper respiratory tract infection 7 (2.5) 4 (4.2) 3 (1.6) 
Ataxia 17 (6.1) 4 (4.2) 13 (7.1) 
Balance disorder 10 (3.6) 2 (2.1) 8 (4.3) 
p < 0.05; **p < 0.01; ***p < 0.001 vs patients receiving no EIAEDs (Fisher’s exact test).
here were no statistically signiﬁcant differences observed between groups of patients w
IAED  (enzyme-inducing antiepileptic drug), SCB (sodium channel blocker), TEAE (treatm34.0 46.2 53.2
be anticipated when it is introduced to a regimen containing
an EIAED, and higher doses of perampanel may  be required to
gain optimal seizure control. However, ultimately perampanel
should always be titrated to an effective and tolerated dose in all
patients, based on treatment response, regardless of concomitant
AEDs (European Medicines Agency, 2012). Prospective studies are
needed to more clearly deﬁne perampanel dosing strategies when
EIAEDs are co-administered.
or without concomitant EIAEDs or non-EIAED SCBs.
One or more EIAEDs
 or
ED
One or more
EIAEDs (n = 758)
One or more EIAEDs/no
non-EIAED SCBs
(n = 579)
One or more EIAEDs/one
or more non-EIAED SCBs
(n = 179)
54 (7.1)*** 41 (7.1) 13 (7.3)
209 (27.6) 158 (27.3) 51 (28.5)
112 (14.8) 84 (14.5) 28 (15.6)
90 (11.9) 67 (11.6) 23 (12.8)
55 (7.3)* 42 (7.3) 13 (7.3)
52 (6.9) 42 (7.3) 10 (5.6)
30 (4.0)** 25 (4.3) 5 (2.8)
35 (4.6) 26 (4.5) 9 (5.0)
33 (4.4) 24 (4.1) 9 (5.0)
34 (4.5) 22 (3.8) 12 (6.7)
19 (2.5)* 15 (2.6) 4 (2.2)
20 (2.6) 14 (2.4) 6 (3.4)
ho were/were not receiving non-EIAED SCBs (Fisher’s exact test).
ent-emergent adverse event).
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Aig. 2. Median percentage changes in seizure frequency per 28 days (Baseline vs Do
n  patients receiving perampanel 2–12 mg  (pooled doses) in combination with 1–3
IAED  (enzyme-inducing antiepileptic drug).
In contrast, concomitant administration of non-EIAED SCBs had
o consistent impact on the efﬁcacy and tolerability of perampanel,
uggesting that clinically signiﬁcant pharmacodynamic interac-
ions between perampanel and SCBs are unlikely. Among patients
ho did not receive any EIAEDs, the apparent low rates of neuro-
oxic TEAEs in those who received one or more SCBs were intriguing
nd may  warrant further investigation. However, as this comprised
he smallest patient group, a chance ﬁnding cannot be excluded.
In terms of the number of AEDs received, perampanel efﬁ-
acy appeared to diminish as the number of concomitant AEDs
ncreased. This may  have reﬂected the likelihood that patients
eceiving more AEDs may  have had more drug-resistant epilepsy.
hile this effect was apparent in patients who were not treated
ith any EIAEDs, it should be considered that, in clinical practice,
atients receiving multiple concomitant AEDs may  also be more
able 6
mpact of the number of concomitant AEDs on TEAE frequencies in patients treated with 
TEAE, n (%) No EIAEDs 
One concomitant
AED (n = 70)
Two concomitant
AEDs (n = 155)
Three 
AEDs (
TEAEs leading to discontinuation 12 (17.1) 24 (15.5) 9 (16
Dizziness 25 (35.7) 46 (29.7) 12 (21
Somnolence 11 (15.7) 19 (12.3) 8 (14
Headache 5 (7.1) 17 (11.0) 6 (10
Fatigue 5 (7.1) 22 (14.2) 6 (10
Irritability 3 (4.3) 14 (9.0) 4 (7.3
Nausea 3 (4.3) 17 (11.0) 4 (7.3
Fall  4 (5.7) 10 (6.5) 4 (7.3
Nasopharyngitis 5 (7.1) 9 (5.8) 3 (5.5
Upper respiratory tract infection 1 (1.4) 3 (1.9) 3 (5.5
Ataxia 2 (2.9) 11 (7.1) 4 (7.3
Balance disorder 4 (5.7) 6 (3.9) 0 (0.0
ED (antiepileptic drug), EIAED (enzyme-inducing antiepileptic drug), TEAE (treatment-eblind Treatment Period) and 50% responder rates (Baseline vs Maintenance Period)
mitant AEDs, including: (A) no EIAEDs, or (B) one EIAED. AED (antiepileptic drug),
likely to be receiving one or more EIAEDs, which could further
reduce perampanel efﬁcacy, in accordance with other observations
reported here. However, in any case, the data reported here indi-
cate that a proportion of patients receiving three concomitant AEDs
may  still be able to derive beneﬁt from adjunctive perampanel.
Reassuringly, patients who received more concomitant AEDs did
not experience more TEAEs.
There are inherent limitations when attempting to evaluate
the impact of concomitant AEDs in a post hoc analysis. These
limitations primarily arise because most patients are treated with
more than one concomitant AED and it is, therefore, difﬁcult to
resolve the contribution of each individual drug. In addition, there
are challenges in deﬁning the precise mechanism of action of
some broad-spectrum AEDs, which may  exhibit sodium chan-
nel blocking activity, yet the degree to which this contributes
perampanel (pooled doses, 2–12 mg).
One EIAED
concomitant
n = 55)
One concomitant
AED (n = 76)
Two concomitant
AEDs (n = 333)
Three concomitant
AEDs (n = 223)
.4) 7 (9.2) 22 (6.6) 18 (8.1)
.8) 23 (30.3) 102 (30.6) 54 (24.2)
.5) 12 (15.8) 44 (13.2) 39 (17.5)
.9) 13 (17.1) 39 (11.7) 22 (9.9)
.9) 10 (13.2) 17 (5.1) 21 (9.4)
) 5 (6.6) 18 (5.4) 16 (7.2)
) 4 (5.3) 10 (3.0) 10 (4.5)
) 1 (1.3) 13 (3.9) 10 (4.5)
) 4 (5.3) 13 (3.9) 9 (4.0)
) 2 (2.6) 15 (4.5) 12 (5.4)
) 0 (0.0) 12 (3.6) 5 (2.2)
) 3 (3.9) 9 (2.7) 5 (2.2)
mergent adverse event).
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o their pharmacologic effects is debatable (e.g., valproic acid,
onisamide). In addition, as a conservative approach, we included
ell-recognized enzyme inducers for which clinically relevant
ffects on perampanel metabolism have not been established.
he complexity of grouping AEDs also limits the investigation of
ther mechanisms of interest, such as inhibition of glutamatergic
eurotransmission, which are most pertinent to perampanel as an
MPA receptor antagonist. Finally, it is important to note the broad
nter-patient variability in terms of the severity of the epilepsy
nd the responsiveness to different treatments.
In conclusion, beyond the known interactions between peram-
anel and EIAEDs, the present analyses suggest that adjunctive
erampanel may  improve efﬁcacy outcomes in patients with
efractory partial-onset seizures with a consistent tolerability pro-
le, regardless of the use of concomitant non-EIAED SCBs or the
verall number of concomitant AEDs. However, the magnitude of
fﬁcacy may  be reduced in the presence of multiple AEDs. These
ndings should be considered when introducing and titrating per-
mpanel to achieve optimal treatment outcomes.
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